Monthly Archives: September 2018

The Rising Tide Of Biotech IPO Valuations
September 24, 2018

The biotech IPO market continues to march forward, with five new offerings expected to price in the next week or so. Investor demand for stories advancing novel innovative therapies remains at historic levels – extending what is now over a

Leave a comment

The Incredible Expanding Universe of Biotech Stocks
September 21, 2018

The biotech sector is unique relative to the rest of the stock market in many ways, but one that is often overlooked: its expansionary public equity market footprint. It’s been well appreciated by market analysts that the universe of U.S.

Leave a comment

Biotech Venture Deal Terms Are More “Startup-Friendly” Than Ever
September 10, 2018

Biotech is booming, with eye-popping new financings seemingly announced daily. The sector is having an epic year for startup fundraising, breaking records for what will end up as the most active private biotech financing year ever. Although overall sentiment in

Leave a comment

IPO: A Go-Go Or A No-No?
September 4, 2018

This blog was written by Jeb Keiper, CFO & CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. Elon Musk has a flare for the dramatic, shocking Wall Street (and others) the first week

Leave a comment